Navigation Links
The Quigley Corporation to Announce Second Quarter Results and Host Audio Web Cast

DOYLESTOWN, Pa., July 30 /PRNewswire-FirstCall/ -- The Quigley Corporation, (Nasdaq: QGLY), today announced it will issue its second quarter results before market open on Wednesday, August 5, 2009.

Ted Karkus, Chairman and CEO, will provide a Company overview including a review of recent activities and second quarter results on a conference call which will be web cast on The Quigley Corporation's web site, (, at 10:00 AM (ET) that morning.

A replay of the conference call will be available for 30 days on the Company web site.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY) ( is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to significantly reduce the severity and duration of the common cold. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has several wholly owned subsidiaries including Quigley Manufacturing Inc., which consists of an FDA approved facility to manufacture COLD-EEZE(R) lozenges and fulfill other contract manufacturing opportunities, and Quigley Pharma Inc., (, which conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.


    Ted Karkus                   Media                    Investor Relations
    Chairman of the Board, CEO   Karen Pineman            Carl Hymans
    The Quigley Corporation      G.S. Schwartz & Co.      G.S. Schwartz & Co.
    (215) 345-0919               212.725.4500             212.725.4500

SOURCE The Quigley Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study
2. Ted Karkus Named CEO of The Quigley Corporation; Robert V. Cuddihy, Jr. Named Chief Operating Officer
3. Dr. Richard Rosenbloom Resumes Services To The Quigley Corporations Pharma Subsidiary
4. Ted Karkus Appointed Interim Chief Executive Officer Of The Quigley Corporation
5. Ted Karkus and Karkus Slate of Directors Prevail in Federal Court, Seated as Directors of The Quigley Corporation; Ted Karkus Elected Chairman of the Board
6. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
7. Dissident Stockholder Ted Karkus Found to Have Undisclosed Financial Arrangements With Dr. Richard A. Rosenbloom, COO Of Quigley Pharma, From 2008 to Date of Proxy: Rosenbloom Suspended Without Pay Pending Further Investigation
8. Karkus Nominees Caution Quigley Shareholders Not to be Fooled by the Companys Latest Announcement
9. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
10. Judge Rejects Quigleys Claims - Karkus Director Candidates Prevail in Federal Court
11. Quigley Corporation Receives Support from Leading Independent Proxy Advisory Firms; RiskMetrics and Glass Lewis Reject Dissident Stockholder Ted Karkus, Citing Failure to Provide Detailed Business Plan
Post Your Comments:
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
(Date:11/25/2015)... ... 2015 , ... Lakeview Health, a Jacksonville-based drug and alcohol ... and show through pictures what a positive difference it makes. The social media ... hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram accounts. Short stories can ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The McHenry County law ... successful appellate decision obtained by Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys ... Workers’ Compensation Comm’n, 2015 IL App (2d) 130884WC. , According to court documents, Adcock ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
(Date:11/25/2015)...  Trovagene, Inc. (NASDAQ: TROV ), a developer ... Officer Antonius Schuh, Ph.D., is scheduled to present a ... Jaffray Healthcare Conference. th Annual Piper ... in New York on Tuesday, ... will be available for one-on-one meetings during the conference. ...
(Date:11/25/2015)... , November 25, 2015 ... self-monitoring blood glucose devices was valued at $11,171.1 million ... a CAGR of 5.7% during 2015 - 2022. The ... and increasing prevalence of diabetes. In addition, the increase ... is also contributing to the growth of the market. ...
Breaking Medicine Technology: